Biosafety materials: Ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system
Yuquan Zhang, Ziyue Li, Julien Milon Essola, Kun Ge, Xuyan Dai, Huining He, Haihua Xiao, Yuhua Weng, Yuanyu Huang
Abstract
Despite multiple virus outbreaks over the past decade, including the devastating coronavirus disease 2019 (COVID-19) pandemic, the lack of accurate and timely diagnosis and treatment technologies has wreaked havoc on global biosecurity. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system has the potential to address these critical needs for tackling infectious diseases to detect viral nucleic acids and inhibit viral replication. This review summarizes how the CRISPR/Cas system is being utilized for the treatment and diagnosis of infectious diseases with the help of biosafety materials and highlights the design principle and in vivo and in vitro efficacy of advanced biosafety materials used to deal with virus attacks.